Methods of Producing Effective T-cell Populations Using Akt Inhibitors

Adoptive cell therapy uses cancer reactive T-cells to effectively treat cancer patients. Producing many persistent T-cells is critical for successful treatments. Researchers at the NCI seek licensing and/or co-development research collaborations for a novel method of producing effective T-cell populations using Akt inhibitors.NIH Ref. No.: E-013-2016Advantages: • No other pharmacologic approach available to effectively uncouple T-cell expansion and differentiation• Produces increased number of persistent, cancer reactive T-cellApplications: • Clinically-feasible method of using small molecules to enhance the efficacy of immunotherapy for advanced cancer patients• Useful for the generation of highly effective cancer reactive T-cellDevelopment Status: Pre-clinical (in vivo)Updated On: Dec 5, 2017Provider Classifications: Date Published: Tuesday, December 5, 2017Patent Application: 62/243,834PCT/US2016/057307Publications: Licensing Contacts: Lead Inventor: Inventor Lab URL: https://irp.nih.gov/pi/nicholas-restifoInv Is lead: LPM Phone: [phone]LPM Email: [e-mail] Classification: Research Materials TherapeuticsDTDT Description: Research Materials TherapeuticsPat Filing Date: 2015-10-20T00:00:002016-10-17T00:00:00Publication Link: http://cancerres.aacrjournals.org/content/75/2/296.longhttp://www.bloodjournal.org/content/bloodjournal/early/2014/10/21/blood-2014-0...

Source: NIH OTT Licensing Opportunities - December 5, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research